Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer
Burk, K.; Gropp, C.; de Riese, W.; Löbenau, S.
Helvetica Chirurgica Acta 52(3-4): 601-603
1985
ISSN/ISBN: 0018-0181 PMID: 3934112 Document Number: 251032
Document emailed within 1 workday
Related Documents
Van der Werf-Messing, B. 1979: Non-metastasized prostate cancer with spread outside the capsule treated with megavolt radiation Nederlands Tijdschrift Voor Geneeskunde 123(19): 778-783Aphinives, P.; Bhudhisawasdi, V.; Sae-seow, O.; Uttaravichien, T. 2006: 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer Journal of the Medical Association of Thailand 89(11): 1885-1889
Covens, A.; O'Connell, G.; Rusthoven, J.; Mazurka, J. 1992: Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer European Journal of Gynaecological Oncology 13(2): 125-130
2013: Metastatic prostate cancer progressing despite androgen suppression: two main options Prescrire International 22(136): 77
Weber, W.; Laffer, U.; Metzger, U. 1993: Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. SAKK Anticancer Research 13(5C): 1839-1840
Ozeki, H.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Nagamine, D.; Ito, Y.; Imajo, K.; Shinagawa, K. 1988: Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(1): 91-95
Ishihara, M.; Kubota, T.; Watanabe, M.; Kawano, Y.; Narai, S.; Yasui, N.; Otani, Y.; Teramoto, T.; Kitajima, M. 1999: Combined antitumour activity of mitomycin C, 5-fluorouracil and interleukin-2 against human colon cancer cells Anticancer Research 19(1a): 313-316
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Ota, K.; Kurita, S.; Nishimura, M.; Ogawa, M.; Kamei, Y.; Imai, K.; Ariyoshi, Y.; Kataoka, K.; Murakami, M.; Oyama, A.; Hoshino, A.; Amo, H.; Kato, T. 1972: Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man Cancer ChemoTherapy Reports 56(3): 373-385
Grieco, A.; Lasorella, A.; Astone, A.; Vagliviello, L.; Bartoloni, C.; Barone, C. 1984: Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). a non-controlled study La Clinica Terapeutica 110(4): 353-358
Sulkes, A.; Uziely, B.; Isacson, R.; Brufman, G.; Biran, S. 1988: Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas Israel Journal of Medical Sciences 24(9-10): 604-610
Sato, S.; Nabeyama, A.; Nakashima, A.; Kanzaki, T.; Matsuo, S.; Ohta, K.; Endoh, A.; Kimura, Y.; Kai, K.; Sasahashi, N. 1992: A case of recurrent liver tumor from gastric cancer responding remarkably to hepatic arterial infusion of large doses of mitomycin C and 5-fluorouracil Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(4): 537-539
Kurihara, M.; Kosaki, G.; Taguchi, T.; Akazawa, S.; Sasaki, T.; Takahashi, H.; Onodera, T.; Endo, M.; Nakagawara, G.; Sano, K. 1995: Quality of life in patients with advanced gastric cancer receiving AO-90, a methionine-free intravenous amino acid solution, with 5-fluorouracil and mitomycin C Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(7): 911-923
Boel, K.; Van Poppel, H.; Goethuys, H.; Derluyn, J.; Vandenbroucke, F.; Popelier, G.; Casselman, J.; Billiet, I.; Vanuytsel, L.; Paridaens, R.; Baert, L. 1999: Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial Anticancer Research 19(3b): 2157-2161
Korman, D.B.; Borisov, A.I.; Maslova, I.A.; Dobroskok, L.B. 1980: Use of adriablastine in the combined chemotherapy of breast cancer patients with bone metastases Voprosy Onkologii 26(8): 20-24
Khayat, D.; Gil-Delgado, M.; Antoine, E.C.; Coeffic, D.; Benhammouda, A.; Grapin, J.P.; Bastian, G. 1998: European experience with irinotecan plus fluorouracil/folinic acid or mitomycin Oncology 12(8 Suppl. 6): 64-67
Athlin, L.; Domellöf, L. 1987: Response of human monocyte phagocytosis to FAM (fluorouracil, adriamycin, mitomycin) Acta Chirurgica Scandinavica 153(4): 279-281
Späti, B.; Jungi, W.F.; Mayr, A.C.; Hammer, B.; Senn, H.J. 1980: Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas Schweizerische Medizinische Wochenschrift 110(27-28): 1076-1078
Gudurić, B.; Semnic, R.; Sterio, B. 1977: Our experiences with mono-and polychemotherapy in carcinoma of the breast Medicinski Pregled 30(3-4): 173-176
Kuwano, M.; Ikezaki, K.; Mamizuka, K.; Komiyama, S.; Seto, H.; Otake, N.; Sugita, M.; Yamaguchi, T.; Kishiye, T.; Fukawa, H. 1983: Potentiation of mitomycin C, 6-mercaptopurine, bleomycin, cis-diamminedichloroplatinum and 5-fluorouracil by mycotrienins and mycotrienols Gan 74(5): 759-766